Two new life science venture capital funds launched recently with $500m to invest in biopharmaceutical and genomics firms, showing that funding for early-stage companies continues to be an attractive investment space, despite the slowdown in initial public offerings – one of two major exits for VC investors.
The new venture capital firm Pivotal bioVenture Partners in San Francisco has launched with $300m from a single limited partner...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
